期刊文献+

重症Graves眼病的治疗——临床内分泌科医师仍面临挑战 被引量:3

Treatment of severe Graves’ophthalmopathy:Clinical endocrinology physicians still face challenges
下载PDF
导出
摘要 Graves眼病是一种器官特异性自身免疫性疾病,成人最常见的眼眶疾病。尽管迄今已有多项基础及临床研究,但其发病机制及有效的治疗措施尚不明确。目前针对重症眼病常用的治疗方法包括静脉糖皮质激素、球后放射治疗以及手术等,但这些均是对症状性治疗,效果并不尽如人意。免疫靶向治疗主要针对Graves眼病发病过程中的诸多靶点,是非常有发展前景的治疗方法,尽管目前临床实践和经验尚有限。无论采取何种治疗手段,戒烟是重症眼病治疗的基础。如何选择最适合于重症眼病的治疗方法并提高其疗效仍是广大临床内分泌医师面临的一项巨大挑战。
出处 《药品评价》 CAS 2013年第15期23-24,26-28,共5页 Drug Evaluation
  • 相关文献

参考文献20

  • 1Butch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management[J]. Endocr Rev, 1993, 14: 747-793.
  • 2Bartalena L, Pinchera A, Marcoeci C. Management of Graves' ophthalmopathy: reality and perspectives[J]. Endocr Rev, 2002, 21: 168-199.
  • 3Lehmannn GM, Garcia-Bates TM, Smith TJ, et al. Regulation of lymphocyte function by PPARgamma: Relevance to thyroid eye disease- related inflammation[J]. PPAR Res, 2008, 2008, 895901.
  • 4Bartley GB, Fatourechi V, Kadrmas EF, et al. Long-term follow-up of Graves' ophthalmopathy in an incidence cohort[J]. Ophthalmology, 1996, 103: 958-962.
  • 5Putta-Manohar S, Perros P. Epidemiology of Graves' orbitopathy[J]. Pediatr Endocrinol Rev, 2010, 7(Suppl 2): 182-185.
  • 6Garrity JA, Bahn RS. Pathogenesis of Graves ophthalmopathy: implications for predicition, prevention and treatment[J]. Am J Ophthalmol, 2006, 142(1): 147-153.
  • 7Rebecca S, Balm. Graves' ophthalmopalhy[J]. N Engl J Med, 2010, 362: 726.
  • 8Ji HL, Sang YL, Jin SY. Risk factors associated with the severity of thyroid-associated orbitopathy in Korean patients[J]. Korean J Ophthalmol, 2010, 24(5): 267-273.
  • 9Tanda ML, Piantanida E, Liparulo L, et al. Prevalence and natural history of Graves' nrbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center[J]. Clin Endocrinol Metab, 2013, 98(4): 1443-1449.
  • 10Bartalen L, Baldeschi L, Dickinison AJ, et al. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy[J]. Thyroid, 2008,18: 333-346.

二级参考文献36

  • 1王迎雪,阎胜利.肿瘤坏死因子α基因多态性与甲状腺相关性眼病相关[J].中华内分泌代谢杂志,2006,22(1):57-58. 被引量:7
  • 2Khalilzadeh O, Noshad S, Rashidi A, et al. Graves' ophthalmopa thy: a review of immunogenetics [ J]. Curr Genomics, 2011,1 (8) :564-575.
  • 3Vaidya B, Imrie H, Perros P, et al. Cyotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid as- sociated orbitopathy [ J ]. Lancet, 1999,354 (9180 ) :743-744.
  • 4Vaidya B,Oakes EJ,Imrie H,et al. CTLA4 gene and Graves's dis-ease:association of Graves' disease with the CTLA4 exon 1 and in- tron 1 polymorphisms, but not with the promoter polymorphism[ J]. Clin Endoerinol (Oxf) ,2003,58 ( 6 ) :732-735.
  • 5Frydecka I, Daroszewski J, Suwalska K, et al. CTLA4 (CD152) gene polymorphism at position 49 in exon 1 in Graves' disease in a Polish population of the Lower Silesian region [ J ]. Arch Immunol Ther Exp(Warsz) ,2004,52(5) :369-374.
  • 6Kamizono S, Hiromatsu Y, Seki N, et al. A polymorphism of the 5 ' flanking region of tumor necrosis factor alpha gene is associated with thyroid-associated ophthalmopathy in Japanese [ J ]. Clin En- docrinol (Oxf) ,2000,52 ( 6 ) :759-764.
  • 7Eckstein A, Quadbeck B, Mueller G, et al. Impact of smoking on the response to treatment of thyroid associated ophthalmopathy [ J ]. Br J Ophthalmol, 2003,87 ( 6 ) : 773-776.
  • 8Trsk F, Tallstedt L, Abraham-Nordling M,et al. Thyroid-associat- ed ophthalmopathy after treatment for Graves'hyperthyroidism with antithyroid drugs or iodine-131 [ J]. J Clin Endocrinol Metab, 2009,94 ( 10 ) :3700-3707.
  • 9HegediOs L, Brix TH, Vestergaard P. Relationship between cigarette smoking and Graves' ophthalmopathy [ J ]. J Endocrinol Invest, 2004,27 ( 3 ) : 265-271.
  • 10Valyasevi RW, Harteneck DA, Dutton CM, et al. Stimulation of adi- pogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma) ,and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts [ J ]. J Clin Endocrinol Metab ,2002,87 ( 5 ) :2352-2358.

共引文献12

同被引文献28

  • 1孙丰源,潘叶,宋国祥,畅继武.促甲状腺激素受体在甲状腺相关眼病球后组织中的基因和蛋白表达[J].中华眼科杂志,2006,42(2):155-158. 被引量:4
  • 2Chang TC,Kao SC,Hsiao YL,et al. Therapeutic responses to corti-costeroids in Grave ’ ophthalmopathy [ J] . J Formos Med Assoc,1996,95(11) :833 -838.
  • 3Rajendram R,Lee RW,Potts MJ,et al. Protocol for the combinedimmunosuppression and radiotherapy in thyroid eye disease ( CIR-TED) trial: A multi-centre, double-masked, factorial randomizedcontrolled trial[ J] . Trials,2008,9:6.
  • 4Kopp P. The TSH receptor and its role in thyroid disease[ J]. CellMol Life Sci,2001,58(9) :1301 -1322.
  • 5Bartalena L, Baldeschi L, Dickinison A J, et al. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy[J]. Thyroid, 2008,18(3) : 333-346.
  • 6Rajendram R, Lee RW, Potts MJ, et al. Protocol for the combined immunosuppression and radiotherapy in thy- roid eye disease(CIRTED) trial: a multi-center, double- masked, factorial randomized controlled trial[J]. Trials, 2008,(9) : 6.
  • 7Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, et al. Treatment modalities for Graves' ophthalmopathy: sys- tematic review and metananlysis[J]. Clin Endocrinol Metab, 2009, 94(8) : 2708-2716.
  • 8孙利平.^(131)Ⅰ联合泼尼松治疗Graves眼病的疗效观察[J].中国实用医药,2011,6(7):26-27. 被引量:4
  • 9王澎,谭建.不同药物影响Graves病^131I治疗效果的研究进展[J].国际放射医学核医学杂志,2011,35(1):9-13. 被引量:2
  • 10蒋炳辰,高永旺,张雪辉,肖国有,姚少红.^(131)碘治疗Graves病的临床价值[J].海南医学,2013,24(12):1735-1737. 被引量:2

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部